Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 13'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
First Look: Tech-led selloff, tariff shifts, AI funding boom
07:38am, Friday, 13'th Feb 2026
Stock News Tech slump hits indexes: A broad risk-off move saw Apple (AAPL) and Cisco (CSCO) lead declines, while Applied Materials (AMAT) rallied on upbeat AI t
Prices, pipelines and patent cliffs: Inside pharma's big reset
06:13am, Friday, 13'th Feb 2026
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Market Today: Tech Sells Off on AI Jitters; M&A, FDA Moves and Policy Shifts
05:35pm, Thursday, 12'th Feb 2026
Guru Stock PicksAl Gore has made the following transactions:Reduce in NTNX by 46.77%Sold out in MCHPAdd in MELI by 2.52%New position in CSLKen Fisher has made t
Renaissance Technologies' Strategic Moves: NVIDIA Corp Sees Significant Reduction
05:04pm, Thursday, 12'th Feb 2026
Exploring the Latest 13F Filing and Investment Shifts Renaissance Technologies (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
03:27pm, Thursday, 12'th Feb 2026
Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
01:02pm, Thursday, 12'th Feb 2026
Novo Nordisk A/S (NYSE: NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE: LLY) as co
2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
10:00am, Thursday, 12'th Feb 2026
AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age.
Vanguard's Mid Cap Growth Filter Fails to Deliver on Its Investor Promise
08:29am, Thursday, 12'th Feb 2026
If you're building a portfolio that needs exposure to mid-cap companies with growth potential, you're choosing between two paths: buying a broad mid-cap fund and accepting whatever mix of value and gr
First Look: McDonald's beats, Hims sued, WBD deal battle
07:39am, Thursday, 12'th Feb 2026
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.
05:10am, Thursday, 12'th Feb 2026
Eli Lilly and Novo Nordisk dominate the weight loss drug market, one that soon may approach $100 billion. One of these players has recently gained market share.
Baron Opportunity Fund Q4 2025 Contributors And Detractors
01:10am, Thursday, 12'th Feb 2026
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of
PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co
06:00pm, Wednesday, 11'th Feb 2026
Insights from the Fourth Quarter 2025 13F Filing PRIMECAP Management (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2025, offe
3 Reasons to Buy Eli Lilly Stock
11:15am, Wednesday, 11'th Feb 2026
Eli Lilly is posting strong results, and that should continue. The drugmaker is dominating in its core therapeutic area.
What Will Drive Eli Lilly Stock's Next Breakout?
08:45am, Wednesday, 11'th Feb 2026
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than
